dasatinib was subsequently escalated to 140 mg/day for 4 weeks, again without response (bone marrow smear and differential blood counts still showed CP-CML). The third generation TKI ponatinib (45 mg/day) was then initiated to further reduce leukemic burden before the planned allogeneic peripheral blood stem cell transplantation from an available 10/10 unrelated donor.
Three weeks after starting ponatinib the patient developed complete visual loss. Ponatinib was immediately stopped and radiological imaging revealed multiple bilateral infarctions in the posterior area of the middle and posterior cerebral artery territories (Figure 1a , arrows). Magnetic resonance imaging (MRI) angiography showed severly narrowed vessels in the circle of Willis bilaterally (Figure 1b) . Digital substraction angiography (DSA) showed caliber changes with high-grade stenosis resembling 'Moyamoya' disease and suggesting vasculitis (Figure 1c ). Infectious problems as well as meningeal leukemia were excluded. Despite a 3-day course of high-dose corticosteroid therapy (1 g per 24 h) together with low-dose aspirin and heparin, the patient's condition deteriorated and had to be mechanically ventilated. Other reasons (for example, microangiopathy, posterior reversible leukencephalopathy syndrome and so on) for the vascular pathology were excluded. The patient subsequently died due to brain death including generalized brain edema and demarcation of bilateral infarctions (Figure 1d ) resulting in compression of the brain stem. Postmortem examination revealed only minimal signs of generalized arteriosclerosis of the large vessels but severe brain edema leading to compression of the brain stem. Histologically, multiple both fresh and old ischemic cerebral insults were seen, without characteristics of cerebral vasculitis.
Recent data from the phase II PACE trial reported serious arterial thrombotic events occurring in 8% of ponatinib-exposed patients including 2% experiencing serious cerebrovascular events. 7 Moreover, the first-line EPIC trial was very recently stopped because of high rates of thrombotic events in ponatinib-exposed patients as well as the FDA asked the manufactorer to suspend marketing and sales of the drug. The exact mechanisms of TKI-induced arterial thrombotic events are still elusive, especially when classical risk factors and hallmarks of generalized arteriosclerosis are missing. In line with our case, recent data from the MDACC described several cases of non-arteriosclerotic vascular events. 8 Moreover, in most cases of vascular complications described so far, clinical events more frequently occurred long after nilotinib treatment initiation. In the case presented here, the total exposure time to nilotinib and ponatinib was 13 months. This is a rather short exposure time and emphasizes the hypothesis of an eventual cross-toxicity between nilotinib and ponatinib. Thus, we are not able to clearly identify which TKI, if any, was responsible for the fatal course. However, our report supports the necessity to carefully evaluate patients receiving either nilotinib or ponatinib for vascular and metabolic changes even in the absence of cardiovascular risk factors. To date, more than 500 fusion genes have been described in hematological malignancies, yet only a small fraction of these are sufficiently common, and with a known clinical impact, to justify routine clinical analysis. 1 For this small subgroup, however, their presence can provide crucial information for diagnosis, prognosis and treatment. For example, the presence of fusion genes such as BCR/ABL1 in chronic myeloid leukemia (CML) and PML/RARA in acute promyelocytic leukemia warrants treatment specifically targeting the fusion proteins. 2, 3 Other gene fusions, for which there might not exist targeted therapies, are used to risk stratify leukemias into different treatment groups; for example, ETV6/RUNX1, TCF3/PBX1 and various MLL fusions in childhood B-cell acute lymphoblastic leukemia (ALL). 4 The proportion of cases harboring known clinically relevant fusion genes varies substantially between hematological malignancies, but in ALL and acute myeloid leukemia (AML) 25-45% of the cases are positive for any of the clinically relevant fusion genes. 4, 5 To what extent the remaining cases harbor novel fusions, perhaps also suitable for targeted treatment, is not known, largely because the process of identifying new gene fusions has been laborious.
CONFLICT OF INTEREST
Here, we describe how RNA sequencing (RNA-seq) can be used as a reliable tool to identify known clinically relevant fusion genes, in addition to novel fusions. Fifteen leukemic cell lines that were derived from ALL, AML or CML containing a known prognostically relevant fusion gene were included in the study (Table 1) . In addition to these, one primary preB-ALL, negative for BCR/ABL1, TCF3/PBX1 and ETV6/RUNX1, but harboring a t(1;5)(q21; Table S1 and Supplementary Materials and Methods). A list of 42 candidate fusion genes was identified using chimerascan 7 followed by a filtering approach. Of these, 31 (74%) could be verified as genuine gene fusions using reverse transcriptase-PCR and Sanger sequencing (Table 1) . Notably, this included all 15 clinically relevant fusion genes previously known to be present in the cell lines. Seven of the remaining verified fusions were reciprocal to previously known fusions and nine were novel. Of the nine novel fusions, seven were expected to produce nonfunctional proteins or no protein, either because the translated regions were fused out of frame or because of fusion to untranslated regions. However, these nonfunctional fusions contained genes such as RUNX1, NUP214 and EBF ( Table 1) that are known to be involved in leukemogenesis in several types of aberrations, for example, in-frame fusions. 1 Hence, it seems as if the establishment of truncating fusion genes is an alternative way to impair the function of important genes during leukemogenesis. Similar out-of-frame fusion genes were recently shown to be present in 31 of 200 AMLs (16%). 8 In the patient sample, a novel in-frame MEF2D/CSF1R fusion consistent with the described t(1;5)(q21;q33) could be identified. Interestingly, a clinical fluorescence in situ hybridization (FISH) analysis with a commercially available probe targeting PDGFRB (Abbott Molecular, Des Plaines, IL, USA) had previously indicated that PDGFRB was the gene rearranged on 5q33. However, CSF1R and PDGFRB are located only 500 bp apart and the commercial FISH probe would not differentiate between a CSF1R and a PDGFRB rearrangement, further illustrating the importance of unbiased RNA-seq in finding this fusion.
The MEF2D/CSF1R transcript, fusing exon 7 of MEF2D to exon 12 of CSF1R, represents a novel fusion whose constituent genes have been described in a single fusion gene each prior to this. 1 The predicted fusion protein retains the MADS-box (a DNAbinding and dimerization domain) from MEF2D and the tyrosine kinase domain of CSF1R (Figure 1a ). In analogy with other oncogenic fusion genes containing receptor tyrosine kinases (such as ETV6/PDGFRB and ZMYM2/FGFR1), it seems plausible that dimerization of the fusion protein through the MADS-box domain renders a constitutively active tyrosine kinase. 9 Normal CSF1 signaling through CSF1R is known to regulate macrophage development, and was recently shown to instruct myeloid lineage fate decisions in hematopoietic stem cells. 10 Although CSF1R mutations were initially reported to be common in AML and myelodysplastic syndrome, 11 this has not been confirmed in later large-scale sequencing studies, 8 indicating that the hybridization-based technique used in the initial study might have had a high false-positive rate. However, two functionally validated CSF1R alterations have been described in hematological malignancies-both in myeloid neoplasms. 12, 13 Hence, the MEF2D/CSF1R fusion gene is the first described CSF1R alteration in a lymphoid neoplasm. To verify that the novel MEF2D/CSF1R fusion gene encodes a constitutively active tyrosine kinase that is necessary for the leukemic cells, we examined the in vitro sensitivity of patientderived leukemic bone marrow cells to two tyrosine kinase inhibitors (TKIs): imatinib, which is a clinically available TKI known to inhibit several tyrosine kinases including CSF1R, and GW2580, an inhibitor with a specific activity against CSF1R (Figure 1b) . 14, 15 This revealed that imatinib impaired cell growth of the leukemic cells carrying MEF2D/CSF1R to a similar degree as that of leukemic cells from a CML carrying BCR/ABL1. Treatment with GW2580 effectively impaired cell growth of the leukemic cells with MEF2D/ CSF1R, whereas CML cells did not respond. Considering that GW2580 specifically inhibits CSF1R, this demonstrates that the leukemic cells are dependent on the activity of the novel MEF2D/ CSF1R fusion protein, identifying the fusion gene as a genuine driver mutation. However, while GW2580 is not available for clinical use, the sensitivity to imatinib suggests that this compound could constitute a viable treatment alternative.
In conclusion, we have demonstrated that unbiased mRNA sequencing can identify a number of known clinically relevant fusion genes as well as novel fusion genes in cell lines and clinical leukemia samples. The identification of a novel MEF2D/CSF1R in a preB-ALL, sensitive to in vitro treatment with imatinib and the CSF1R-specific inhibitor GW2580, also demonstrates that RNA-seq may have a direct clinical impact for treatment selection. Fusion genes previously known to be present in the sample are indicated in bold type. In vitro sensitivity to tyrosine kinase inhibitors. Bone marrow derived cells representing ALL (with MEF2D/CSF1R), CML (with BCR/ABL1), and normal bone marrow were cultured in the presence of imatinib or GW2580 at the indicated concentrations. Corresponding cultures containing only DMSO, in concentrations matching those of the tyrosine kinase inhibitor solutions, were used for normalization. Imatinib hampered the growth of both ALL and CML cells, whereas the CSF1R-specific inhibitor GW2580 had a marked effect only on the ALL cells carrying the MEF2D/CSF1R fusion gene.
